Completed PHASE2 INTERVENTIONAL 2-arm NCT01156753

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer (EMERGE)

A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Sponsor: Celldex Therapeutics

Conditions Breast Cancer

Interventions CDX-011 Investigator's Choice chemotherapy

Updated 8 times since 2017 Last updated: Jun 26, 2017 Started: Jul 31, 2010 Primary completion: Oct 31, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Celldex Therapeutics and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Aug 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celldex Therapeutics

Data source: Celldex Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Charlotte, United States , Cincinnati, United States , Columbia, United States , Detroit, United States , Knoxville, United States , Lake Success, United States , Long Beach, United States , Los Angeles, United States and 12 more locations